operations60Industry96Business102Management124Principal and selling stockholder152Certain relationships and related party transactions153Description of certain indebtedness166Description of capital stock168Shares eligible for future sale177Material United States federal income and estate tax consequences to non-U.S. holders179Underwriting (Conflicts of interest)182Legal matters190Experts190Where you can find more information190Index to financial statementsF-1Zoetis Inc., Pfizer Inc., the debt-for-equity exchange parties and the underwriters have not authorized anyone to provide any information other than
Accordingly, unless the context requires otherwise, statements relating to our history in this prospectus describe the history of Pfizer’s animal health business unit.Currency amounts in this prospectus are stated in United States dollars, unless otherwise indicated.Unless otherwise indicated, information contained in this prospectus concerning our industry and the markets in which we operate, including our general expectations and market position, market opportunity
billion for the year ended December 31, 2011, we are the largest animal health medicines and vaccines business, with our products sold in more than 120 countries and across eight core species and five major product categories.With our sales organization of approximately 3,400 employees, we directly market our portfolio of more than 300 product lines to livestock producers and
These risks include, but are not limited to:•emerging restrictions and bans on the use of antibacterials in food-producing animals;•perceived adverse effects on human health linked to the consumption of food derived from animals that utilize our products;•increased regulation or decreased governmental support relating to the raising, processing or consumption of food-producing animals;•an outbreak of infectious disease carried by animals;•adverse weather conditions and the availability of natural resources;•adverse global economic conditions;•failure of our R&D, acquisition and licensing efforts to generate new products;•failure to achieve the expected benefits of the Separation or the Distribution, which include improved strategic and operational efficiency, the
combined financial statements include expense allocations for certain support functions that are provided on a centralized basis within Pfizer, such as expenses for business technology, facilities, legal, finance, human resources, and, to a lesser
practicable, proportional cost allocation methods (e.g., using third-party sales, headcount, animal health manufacturing costs, etc.) depending on the nature of the services and/or costs.The financial statements included in this prospectus may not be indicative of our future performance and do not necessarily reflect what our financial position and results of operations would have been
discussion and analysis of financial condition and results of operations” and our combined financial statements and notes thereto included elsewhere in this prospectus.13Table of ContentsStatement of operations data:Pro FormaHistoricalNine MonthsEndedYear EndedDecember 31,(a)Nine MonthsEndedYear EndedDecember 31,(a)(MILLIONS OF DOLLARS, EXCEPT PERSHARE AMOUNTS)September 30,20122011September 30,2012October 2,2011201120102009Revenues$3,160$4,233$3,160$3,106$4,233$3,582$2,760Costs and expenses(b)2,5373,7712,4692,6343,6853,2022,568Restructuring charges and certain acquisition—related costs5515455108154202340Income/(loss) before provision/(benefit) for taxes on income/(loss)568308636364394178(148)Provision/(benefit) for taxes on income/(loss)16411319012614667(47)Net income/(loss) before allocation to noncontrolling interests404195446238248111(101)Less: Net income/(loss) attributable to noncontrolling interests—3—231(1)Net income/(loss) attributable to Zoetis$404$192$446$236$245$110$(100)Earnings per common share—basic(c)$0.81$0.38NANANANANAEarnings per common share—fully diluted(c)$0.81$0.38NANANANANABalance sheet data:(MILLIONS OF DOLLARS)At September 
30,2012Pro FormaHistoricalWorking capital$1,858$1,818Property, plant and equipment, less accumulated depreciation1,2291,204Total assets5,8375,904Allocated long-term debt(d)—580Long-term debt(e)3,640—Total liabilities4,7781,795Total Zoetis equity(f)1,0444,094Certain amounts may reflect rounding adjustments.(a)Starting in 2011, includes the King Animal Health business, or KAH, acquired as part of Pfizer’s acquisition of King Pharmaceuticals, Inc., commencing on the
restrictions or bans, expanded regulations or public pressure to discontinue or reduce use of antibacterials in food-producing animals, which could materially adversely affect our operating results and financial condition.Perceived adverse effects on human health linked to the consumption of food derived from animals that utilize our products could cause a decline in
impairment of goodwill or identifiable intangible assets could have a material adverse effect on our operating results and financial position.Risks related to research and developmentOur R&D, acquisition and licensing efforts may fail to generate new products and brand lifecycle developments.Our future success depends on both our existing product portfolio and our pipeline of new products, including new products that we may develop through
These concerns and the related harm to our reputation could materially adversely affect our operating results and financial condition, regardless of whether such reports are accurate.Our business is subject to substantial regulation.We will not be able to market new products unless and until we have obtained all required regulatory approvals in each jurisdiction where we propose to market those products.
regulations or requirements, or the political environment in a particular country, may affect our ability to engage in business transactions in certain markets, including investment, procurement and repatriation of earnings.Foreign exchange rate fluctuations and potential currency controls affect our results of operations, as reported in our financial statements.We conduct operations in many areas of the world, involving transactions denominated in a variety of currencies.
corporate requirements, including dividends;•increasing our vulnerability to general adverse economic and industry conditions;•exposing us to the risk of increased interest rates as certain of our borrowings are and may in the future be at variable rates of interest;•limiting our flexibility in planning for and reacting to changes in the animal health industry;•placing us at a competitive disadvantage to other, less leveraged competitors;•impacting our effective tax rate; and•increasing our cost of borrowing.In addition, the instruments governing our indebtedness contain restrictive covenants that will limit our ability to engage in activities that may be in our long-term best interest.
agreements and relationships could be impacted, all of which may adversely affect our ability to run our business as described herein and may have a material adverse effect on our operating results and financial condition.The Distribution or future sales by Pfizer or others of our common stock, or the perception that the Distribution or such sales may occur, could
Accordingly, you will not have the same protections afforded to stockholders of companies that are subject to all of the corporate governance requirements of the NYSE.As a result of the Separation, we will lose Pfizer’s brand, reputation, capital base and other resources.Prior to the completion of this offering, as a business unit of Pfizer, we have generally used the name “Pfizer Animal Health,” and we believe the association with Pfizer has contributed to our
with other Pfizer business units that may be higher or lower than the comparable expenses we would have actually incurred, or will incur in the future, as a standalone company;•our cost of debt and our capital structure will be different from that reflected in our historical combined financial statements;•significant increases may occur in our cost structure as a result of this offering, including costs related to public company reporting, investor